Hierarchy of immunogenicity of Plasmodium falciparum merozoite antigens and vaccine candidates in first human infection
- 1Burnet Institute
Abstract
Background: Merozoite antigens are targets of acquired immunity and are promising targets for next-generation malaria vaccines and serosurveillance tools. However, the immunogenicity of each antigen and their induction of antibodies following infection remains unclear, impacting vaccine design, antigen selection in serosurveillance, and our understanding of naturally-acquired immunity. Methods: To address this, we assessed IgG and IgM responses to whole merozoites and individual merozoite antigens in 81 malaria-naive adults who experienced a blood-stage P. falciparum Controlled Human Malaria Infection (CHMI). Results: Significant acquisition of IgG and IgM against whole merozoites could be detected as early as two weeks after infection. For IgG responses, a strong hierarchy of immunogenicity among merozoite antigens was observed, with several prominent antigen targets. In contrast, IgM was acquired to most antigens and was less hierarchical with a broader and less antigen-dominant acquisition profile. Participants clustered into distinct immune-acquisition groups according to the breadth and magnitude of their antibody responses, suggesting that individual variation in the development of malaria immunity begins as early as first exposure. Conclusions: Our findings provide important insights into the immunogenicity of merozoite antigens under consideration for vaccine development and identify antigens that could be used in the development of malaria sero-surveillance tools
Related
- Acute Pancreatitis as a Rare Complication of Plasmodium falciparum Malaria: A Case Report
- Human hemoglobin protects the parasite cytoskeleton during Plasmodium falciparum gametocyte development
- Plasmodium falciparum: hrp3 promoter region is associated with stage-specificity and episomal recombination
- Identification of Plasmodium falciparum var1CSA and var2CSA domains that bind IgM natural antibodies
- Thermal proteome profiling identifies new drug targets in Plasmodium falciparum parasites
BibTeX
@misc{waterhouse2026hierarchy,
title = {{Hierarchy of immunogenicity of Plasmodium falciparum merozoite antigens and vaccine candidates in first human infection}},
author = {J. Waterhouse and D. H. Opi and L. Reiling and L. Yeoh and K. Pekin and E. Takashima and A. Thomas and H. Nagaoka and J. S. McCarthy and C. R. Engwerda and B. E. Barber and M. J. Boyle and J. G. Beeson},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.18.26365849},
url = {https://www.medrxiv.org/content/10.64898/2026.10.18.26365849v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Hierarchy of immunogenicity of Plasmodium falciparum merozoite antigens and vaccine candidates in first human infection
AU - J. Waterhouse
AU - D. H. Opi
AU - L. Reiling
AU - L. Yeoh
AU - K. Pekin
AU - E. Takashima
AU - A. Thomas
AU - H. Nagaoka
AU - J. S. McCarthy
AU - C. R. Engwerda
AU - B. E. Barber
AU - M. J. Boyle
AU - J. G. Beeson
PY - 2026
DA - 2026/10/18
PB - medRxiv
DO - 10.64898/2026.10.18.26365849
UR - https://www.medrxiv.org/content/10.64898/2026.10.18.26365849v1
AB - Background: Merozoite antigens are targets of acquired immunity and are promising targets for next-generation malaria vaccines and serosurveillance tools. However, the immunogenicity of each antigen and their induction of antibodies following infection remains unclear, impacting vaccine design, antigen selection in serosurveillance, and our understanding of naturally-acquired immunity. Methods: To address this, we assessed IgG and IgM responses to whole merozoites and individual merozoite antigens in 81 malaria-naive adults who experienced a blood-stage P. falciparum Controlled Human Malaria Infection (CHMI). Results: Significant acquisition of IgG and IgM against whole merozoites could be detected as early as two weeks after infection. For IgG responses, a strong hierarchy of immunogenicity among merozoite antigens was observed, with several prominent antigen targets. In contrast, IgM was acquired to most antigens and was less hierarchical with a broader and less antigen-dominant acquisition profile. Participants clustered into distinct immune-acquisition groups according to the breadth and magnitude of their antibody responses, suggesting that individual variation in the development of malaria immunity begins as early as first exposure. Conclusions: Our findings provide important insights into the immunogenicity of merozoite antigens under consideration for vaccine development and identify antigens that could be used in the development of malaria sero-surveillance tools
ER -